Scandion Oncology Yönetim

Yönetim kriter kontrolleri 1/4

Scandion Oncology CEO'su Francois Martelet, Jan2023 tarihinde atandı, in görev süresi 1.83 yıldır. şirketin hisselerinin 0.005% doğrudan sahiptir ve bu hisselerin değeri SEK 810.47 dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.8 yıl ve 3.2 yıldır.

Anahtar bilgiler

Francois Martelet

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	1.8yrs
CEO sahipliği	0.005%
Yönetim ortalama görev süresi	1.8yrs
Yönetim Kurulu ortalama görev süresi	3.2yrs

Son yönetim güncellemeleri

Recent updates

We Think Scandion Oncology (STO:SCOL) Needs To Drive Business Growth Carefully

Aug 02

Companies Like Scandion Oncology (STO:SCOL) Are In A Position To Invest In Growth

Feb 01

Here's Why We're Not Too Worried About Scandion Oncology's (STO:SCOL) Cash Burn Situation

May 26

We're Hopeful That Scandion Oncology (NGM:SCOL) Will Use Its Cash Wisely

Jan 06

CEO

Francois Martelet (64 yo)

1.8yrs

Görev süresi

Dr. Francois Regis Martelet, M.D. is a Non-executive Director of Novigenix SA since June 2019. He had been the Chief Executive Officer of Vivesto AB (formerly known as Oasmia Pharmaceutical AB (publ)) sinc...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jan Stenvang	Chief Scientific Officer	1.8yrs	Veri yok	0.58% SEK 108.1k
Francois Martelet	Chief Executive Officer	1.8yrs	Veri yok	0.0048% SEK 894.3
Johnny Stilou	Chief Financial Officer	3.3yrs	Veri yok	0.0057% SEK 1.1k
Morten Nissen	General Counsel	no data	Veri yok	Veri yok
Mads Kronborg	Head of External Communication	2.8yrs	Veri yok	Veri yok
Lars Damstrup	Chief Medical Officer	1.8yrs	Veri yok	Veri yok

1.8yrs

Ortalama Görev Süresi

Deneyimli Yönetim: SCOL 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Palle Christophersen	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Richard Schilsky	Member of Clinical Advisory Board	3.6yrs	Veri yok	Veri yok
Alejandra Maria Cristina Mork	Independent Deputy Chairman of the Board	2.6yrs	Veri yok	Veri yok
Eric Cutsem	Member of Clinical Advisory Board	3.2yrs	Veri yok	Veri yok
Josep Tabernero Caturla	Member of Clinical Advisory Board	3.2yrs	Veri yok	Veri yok
Susan Bates	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Keld Jorgensen	Independent Director	2.6yrs	Veri yok	Veri yok
Thomas T. Seufferlein	Member of Clinical Advisory Board	3.2yrs	Veri yok	Veri yok
Martin Moller	Independent Chairman of the Board	3.5yrs	Veri yok	0.0027% SEK 501.0
Michel Ducreux	Member of Clinical Advisory Board	less than a year	Veri yok	Veri yok
Per Pfeiffer	Independent Director	less than a year	Veri yok	Veri yok

3.2yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: SCOL 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.2 yıldır).

Scandion Oncology Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Scandion Oncology A/S, Annual General Meeting, Apr 24, 2024

Scandion Oncology A/S Appoints Lars Damstrup, MD, PhD, as Chief Medical Officer

Scandion Oncology Appoints Jan Stenvang, Ph.D., Chief Scientific Officer and Member of Executive Management

Scandion Oncology Appoints Francois Martelet as New Chief Executive Officer, Effective from January 2, 2023

High number of new and inexperienced directors

Scandion Oncology A/S Announces CEO Changes

Recent updates

Price target decreased by 81% to kr0.60

Scandion Oncology (Scandion) Announces Topline Data for the Corist Part 3

New major risk - Shareholder dilution

New major risk - Financial position

Scandion Oncology Reports Second Confirms Partial Response in the Phase IIa CORIST Part 3 Trial

New major risk - Revenue and earnings growth

Scandion Oncology A/S to Report Q3, 2024 Results on Nov 27, 2024

New major risk - Market cap size

Scandion Oncology Reports Positive Topline Phase IIa Data from the CORIST Part 3 Trial

Scandion Oncology A/S, Annual General Meeting, Apr 24, 2024

Scandion Oncology Receives Notice of Allowance for Patent to Enhance US Patent Exclusivity on SCO-101

Price target decreased by 13% to kr2.80

Scandion Oncology Announces Positive Data from Part 2 of its International Multi-Center CORIST Open Label Phase IIa Trial

Scandion Oncology Successfully Completes Phase Ib Pantax Trial Is and Establishes the Maximal Tolerated Dose with Positive Safety Profile and Pharmacokinetic Data

Scandion Oncology A/S Appoints Lars Damstrup, MD, PhD, as Chief Medical Officer

Scandion Oncology A/S Announces Data from PANTAX Trial to Be Presented At ESMO Congress 2023

The European Patent Office Announces Intention to Grant of Composition-Of-Matter Patent for Scandion Oncology's Lead Compound SCO-101

Forecast to breakeven in 2024

Price target decreased by 31% to kr3.40

Forecast to breakeven in 2024

Price target increased by 27% to kr4.95

Scandion Oncology Receives Opinion from the European Patent Office on Composition of Matter Patent-Application for Lead Compound SCO-101

Scandion Oncology Appoints Jan Stenvang, Ph.D., Chief Scientific Officer and Member of Executive Management

Forecast to breakeven in 2024

Scandion Oncology Appoints Francois Martelet as New Chief Executive Officer, Effective from January 2, 2023

Scandion Oncology A/S to Report Fiscal Year 2022 Results on Mar 22, 2023

Consensus revenue estimates fall by 63%

Price target decreased to kr3.90

High number of new and inexperienced directors

Scandion Oncology Initiates Part 3 of CORIST Phase II Trial Studying Scandion’s Lead Compound SCO-101 as Combination Treatment in Patients with Metastatic Colorectal Cancer

Scandion Oncology Announce Topline Results from Part 2 of the Corist Phase II Trial

Scandion Oncology A/S Announces CEO Changes

Scandion Oncology Announces Change to Its Executive Management

Scandion Oncology A/S Receives Approvals for Next Parts of the Corist Trial

Scandion Oncology Extends PANTAX Trial Due to Better-Than-Expected Tolerability of SCO-101

We Think Scandion Oncology (STO:SCOL) Needs To Drive Business Growth Carefully

Consensus forecasts updated

Consensus forecasts updated

Scandion Oncology Announces Resignation of Thomas Feldthus from the Board of Directors

Scandion Oncology A/S Announces Chief Medical Officer Change

Price target increased to kr26.00

High number of new and inexperienced directors

Scandion Oncology A/S Expands Clinical Development with Internationalization of the CORIST-Trial

Companies Like Scandion Oncology (STO:SCOL) Are In A Position To Invest In Growth

Scandion Oncology A/S Announces That Data from CORIST-Trial to Be Presented At ASCO Gastrointestinal Cancers Symposium

Scandion Oncology Receives Approval for Initiating the CORIST Part 2 Trial

Scandion Oncology Receives German Trial Approval for PANTAX Ib Study

Chief Financial Officer Carit Andersen has left the company

Alligator Bioscience AB and Scandion Oncology A/S Present Promising Preclinical Data

Scandion Oncology A/S Reports Positive Interim Results from the Corist Phase II Study

Here's Why We're Not Too Worried About Scandion Oncology's (STO:SCOL) Cash Burn Situation

Scandion Oncology Appoints Dr. Maj Hedtjärn as COO and Head of R&D Operations

Scandion Oncology A/S Adjusts the Pantax Pancreatic Cancer Study

Scandion Oncology A/S Finalizes the First 12 Patients in CORIST Study

We're Hopeful That Scandion Oncology (NGM:SCOL) Will Use Its Cash Wisely

New 90-day low: kr22.20

New 90-day low: kr34.30

New 90-day low: kr35.00

Scandion Oncology A/S Announces Modified Timelines for Clinical Studies

Scandion Oncology A/S Receives Final Approval from the Danish Medicines Agency and Ethical Committee for Start of A Clinical Trial in Patients with Pancreatic Cancer

Scandion Oncology Appoints Bo Rode Hansen as President, Effective October 1, 2020

An unknown buyer acquired 3.96% stake in Scandion Oncology A/S (NGM:SCOL) from Saniona AB (publ) (OM:SANION) for for $2.3 million.

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş